Cisen Pharmaceutical Ltd. Class A

Cisen Pharmaceutical Ltd. Class A

SSSE:603367
12.69
CNY
-0.05
(-0.39%)
0.86EPS
16.98P/E
6.58BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.87
6.73
7.08
7.27
7.83
8.39
9.11
8.12
8.38
8.95
9.84
8.76
7.6
7.38
Basic EPS, GAAP
0.65
0.62
0.7
0.7
0.97
1.11
1.14
0.97
0.74
0.77
1.15
1.12
0.93
0.86
Free Cash Flow per Basic Share
- -
-0.06
0.7
0.71
1.1
0.81
0.17
0.51
0.4
0.49
0.96
1.03
0.89
- -
Dividend per Share
0.23
0.15
0.16
0.16
0.14
0.16
0.26
0.62
0.27
0.31
0.34
0.67
0.4
0.57
Book Value per Share
5.37
5.37
5.94
6.5
8.21
9.21
10.09
10.59
11.15
11.76
12.65
13.14
13.67
14.06
Tangible Book Value per Share
4.84
4.84
5.4
5.96
7.79
8.8
9.63
10.13
10.69
11.29
12.18
12.69
13.24
13.63
Basic Weighted Avg Shares
321
355
353
353
379
454
451
452
452
454
453
454
453
452
Sales/Revenue/Turnover
2,206
2,388
2,497
2,565
2,963
3,808
4,113
3,674
3,783
4,066
4,462
3,982
3,445
3,336
Operating Margin (%)
10.71
11.56
12.49
11.91
14.67
14.9
13
11.38
7.24
8.6
13.45
13.03
10.93
10.49
Depreciation Expense
- -
172
193
199
188
178
164
160
219
230
234
223
201
- -
Net Income, GAAP
208
220
247
247
367
504
515
439
334
350
521
509
421
387
Effective Tax Rate (%)
13.46
14.61
13.94
15.41
13.46
11.43
11.56
9.73
0.66
3.8
11.82
10.57
14.22
13.3
Profit Margin (%)
9.44
9.22
9.89
9.63
12.4
13.22
12.51
11.94
8.83
8.61
11.68
12.78
12.23
11.6
Working Capital
298
103
313
762
2,166
2,614
2,897
2,666
2,926
3,463
3,600
3,473
3,986
4,531
LT Debt
- -
- -
- -
160
- -
- -
- -
1
11
101
133
9
29
21
Total Equity
1,726
1,901
2,099
2,299
3,724
4,178
4,574
4,802
5,056
5,356
5,766
5,987
6,231
6,410
Return on Invested Capital (%)
10.19
10.55
10.71
9.42
11.39
12.64
11.61
8.85
6.37
6.5
9.07
8.48
6.94
6.19
Return on Capital (%)
12.2
11.74
11.85
10.62
11.74
12.76
11.63
9.16
6.59
6.57
9.14
8.46
6.75
6.09
Return on Common Equity (%)
12.59
12.15
12.35
11.24
12.2
12.75
11.76
9.36
6.78
6.74
9.43
8.72
6.94
6.22

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
16
9
6
LT Borrowings
24
22
19
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
453
453
453
Market Capitalization
7,620
5,809
6,579

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,416
5,787
5,746
Cash, Cash Equivalents & STI
3,203
3,651
3,430
Accounts Receivable, Net
703
709
713
Inventories
616
591
611
Total Current Liabilities
1,164
1,277
1,215
Payables & Accruals
- -
- -
- -
ST Debt
16
9
6
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.5%
5.36%
4.07%
Free Cash Flow
26.07%
18.03%
-14.38%
Net Income, GAAP
8.36%
2.05%
-17.22%
Sales/Revenue/Turnover
4.01%
-0.81%
-13.48%
Total Cash Common Dividend
25.81%
5.14%
-39.94%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,149
922
932
979
3,982
2025
920
820
- -
861
3,445
2026
850
843
782
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.36
0.24
0.28
0.24
1.12
2025
0.32
0.19
- -
0.09
0.93
2026
0.29
0.3
0.18
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.44
- -
0.22
0.67
2025
- -
0.22
- -
0.18
0.4
2026
- -
0.16
0.22
- -
- -

Company Description

CEO
Zhen Xin Du
Full Time Employees
3,114
Sector
Health technology
Industry
Medical specialties
Address
Tongji Sci-tech Industrial Park Jining SD China 272073
IPO Date
Sep 29, 2017
Business
Cisen Pharmaceutical Co., Ltd. (603367.SS) manufactures and sells pharmaceutical products principally in China and internationally. The company offers a broad portfolio exceeding 400 products including large-volume parenterals, small-volume injectables, oral rehydration salts, eye drops, ointments, lyophilized powders for injection, pre-filled injections, tablets, capsules, and active pharmaceutical ingredients; core therapeutic categories encompass chemical drug preparations such as liver disease drugs, antitumor and auxiliary drugs, nutrition preparations, contrast agents, antibiotics, digestive system agents, sedation anesthesia products, cardiovascular drugs, cough and asthma medications, immunomodulators, infusions, therapeutic infusions, polypropylene ampoules, external preparations, psychotropic medicines, antiviral medicines, antidiabetic agents, gastrointestinal treatments, parenteral nutrition, respiratory drugs, and anti-depression therapies. Founded in 1970 as Jining No. 3 Pharmaceutical Factory, renamed Shandong Lukang Cisen Pharmaceutical Co., Ltd. in 1998 and Cisen Pharmaceutical Co., Ltd. in 2011, the company is headquartered at No. 16 Tongji Road, High-Tech Zone, Jining, Shandong Province, China, and operates four industrial parks covering 1,333,400 square meters with nearly 5,000 employees. In recent developments, Cisen Pharmaceutical allocated CNY 200 million to innovation programs in 2023 and pursues partnerships with international research institutions and leading Chinese universities to advance next-generation biologics and R&D capabilities; the company listed on the Shanghai Stock Exchange main board in 2017, planned a medicine unit spin-off for the Shenzhen Stock Exchange in 2023 before scrapping it due to capital market changes, and reported third-quarter 2025 operating revenue of RMB 844 million with net profit growth of 19.61% year-over-year.